Skip to main content

Advertisement

SpringerLink
Log in

Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population

  • Research Article
  • Published:
Tumor Biology

Abstract

The objective of this study was to determine whether p53 codon 47 and codon 72 polymorphisms are associated with increased risk of lung cancer in Bangladeshi population. We carried out a case-control study and examined the genotype distribution Pro47Ser and Arg72Pro single-nucleotide polymorphisms along with tobacco smoking in the predisposition of lung cancer by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach. The study included 106 lung cancer patients and 116 control subjects from Bangladesh. Lung cancer risk was estimated as odds ratio (OR) and 95 % confidence interval (CI) using conditional logistic regression models adjusting for age, sex, and smoking. No significant association was found between Pro47Ser SNP and lung cancer. The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in lung cancer were 25.5, 37.7, and 36.8 %, respectively; frequencies in the controls were 53.4, 30.2, and 16.4 %, respectively (p < 0.01). The Arg/Pro and Pro/Pro genotype were significantly associated with increased risk of lung cancer (OR = 2.51, 95 % CI = 1.38–4.82 and OR = 4.62, 95 % CI = 2.31–9.52, respectively) compared with the Arg/Arg genotype. The combined frequency of Arg/pro and Pro/Pro genotype was also found to be associated with elevated risk of lung cancer (OR = 3.36, 95 % CI = 1.90–5.94, p < 0.01). However, no significant relationship was found between age, sex, and histological subtypes of lung cancer with p53 codon 72 genotype distributions. When classified by smoking status, the effects of Arg72Pro polymorphism on lung cancer risk was only found to be significant (χ 2 = 33.94, p = 0.00000004) in case of heavy smokers (40 packs per year or more). We conclude that not Pro47Ser SNP but Arg72Pro SNP is involved in susceptibility to developing lung cancer, at least in Bangladeshi population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statstics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Hirsch FR, Franklin WA, Gazdar AF, Bunn Jr PA. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res. 2001;7:5–22.

    CAS  PubMed  Google Scholar 

  3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer. 2010. Available from: http://globocan.iarc.fr; last accessed: August 1, 2013.

  4. Sato M, Shames DS, Gazdar AF, et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2(4):327–43.

    Article  PubMed  Google Scholar 

  5. Stewart BW, Kleihues P, editors. World cancer report. Lyon: IARC Press; 2003.

    Google Scholar 

  6. Koo LC, Hoo JH. Worlwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol. 1990;19:14–23.

    Article  Google Scholar 

  7. Tang L, Zirpol GR, Jayaprakash V, et al. Cruciferous vegetable intake is inversely associated with lung cancer risk among smokers: a case control study. BMC Cancer. 2010;10:162.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Alexandrie AK, Sundberg MI, Seidegard J. Genetic susceptibility to lung cancer with susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994;15:1785–90.

    Article  CAS  PubMed  Google Scholar 

  9. Syrjanen KJ. HPV infections and lung cancer. J Clin Pathol. 2002;55:885–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systemic review and meta-analysis. Mutagenesis. 2003;18:377–85.

    Article  CAS  PubMed  Google Scholar 

  11. Levine AJ. p53, the cellular gate keeper for growth and division. Cell. 1997;88:323–31.

    Article  CAS  PubMed  Google Scholar 

  12. Borjesen SE, Nordestgaard BG. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle. 2008;7:158–63.

    Article  Google Scholar 

  13. Viallet J, Minna JD. Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer. Am J Respir Cell Mol Biol. 1990;2:225–32.

    Article  CAS  PubMed  Google Scholar 

  14. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.

    Article  CAS  PubMed  Google Scholar 

  15. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.

    Article  CAS  PubMed  Google Scholar 

  16. Vousden KH, Lane DP. p53 in health and disease. Nature Rev Mol Cell Biol. 2007;8:275–83.

    Article  CAS  Google Scholar 

  17. Spitz MR, Wei Q, Li G, et al. Genetic susceptibility to tobacco carcinogenesis. Cancer Invest. 1999;17:661–2.

    Article  Google Scholar 

  18. Takahashi T, Suzuki H, Hida T, et al. The p53 gene is very frequently mutated in small cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 1991;6:1775–8.

    CAS  PubMed  Google Scholar 

  19. Ahuja HG, Testa MP, Cline MJ. Variation in the protein coding region of the p53 gene. Oncogene. 1990;5:1409–10.

    CAS  PubMed  Google Scholar 

  20. Felix CA, Brown DL, Mitsudomi T, Ikagaki N, Wong A, Wasserman R, et al. Polymorphism at codon 36 of the p53 gene. Oncogene. 1994;9(1):327–8.

    CAS  PubMed  Google Scholar 

  21. Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet. 1993;53:752–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, et al. Molecular basis for heterogenecity of the human p53 protein. Mol Cell Biol. 1986;6:4650–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Weston A, Perrin LS, Forrester K, et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev. 1992;1:481–3.

    CAS  PubMed  Google Scholar 

  24. Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene. 1991;6:1691–2.

    CAS  PubMed  Google Scholar 

  25. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21(48):7435–51.

    Article  CAS  PubMed  Google Scholar 

  26. Pietsch EC, Humbey O, Murphy ME. Polymorphisms at the p53 pathway. Oncogene. 2006;25:1602–11.

    Article  CAS  PubMed  Google Scholar 

  27. Matlashewski GJ, Tuck S, Pim D, et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Beckman G, Birgander R, Sjalander A, Saha N, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44:266–70.

    Article  CAS  PubMed  Google Scholar 

  29. Zhang XM, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006;7:110–7.

    Article  Google Scholar 

  30. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–34.

    Article  CAS  PubMed  Google Scholar 

  31. Murata M, Tagawa M, Kimura H, et al. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-relaed non-small cell lung cancer patients. Int J Oncol. 1998;12:577–81.

    CAS  PubMed  Google Scholar 

  32. Peller S, Halperin R, Scheneider D, et al. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep. 1999;6:193–7.

    CAS  PubMed  Google Scholar 

  33. Wang YC, Lee HS, Chen SK, et al. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer. 1999;35:226–30.

    Article  CAS  PubMed  Google Scholar 

  34. Makni H, Franco EL, Kaiano J, et al. P53 polymorphisms in codon 72 and risk of human papilloma virus-induced cervical cancer: effect of inter laboratory variation. Int J Cancer. 2000;87:528–33.

    Article  CAS  PubMed  Google Scholar 

  35. Zehbe I, Voglino G, Willander E, et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors fopr cervical cancer development. Cancer Res. 2001;61:608–11.

    CAS  PubMed  Google Scholar 

  36. Helland A, Langerod A, Johnsen H, et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:530–1.

    Article  CAS  PubMed  Google Scholar 

  37. Hildesheim A, Schiffman M, Brinton LA, et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531–2.

    Article  CAS  PubMed  Google Scholar 

  38. Josefsson AM, Magnusson PK, Yliatilo N, Magnusson P, Quarforth-Tubbin P, Ponten J, et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531–2.

    Article  CAS  PubMed  Google Scholar 

  39. Zhou C, Chen H, Wang A. P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects. Tumor Biol. 2013;34(5):2961–9.

    Article  CAS  Google Scholar 

  40. Chua W, Nq D, Choo S, et al. Effect of MDM2 SNP 309 and p53 codon 72 polymorphism on lung cancer risk and survival among non-smoking Chienese women inSingapore. BMC Cancer. 2010;10:88.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hancox RJ, Poulton R, Welch D, et al. Accelerated decline on lung fuction in cigeratte smokers is associated with TP53/MDM2 polymorphism. Hum Genet. 2009;126(4):559–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Qiao Q, Hu W. The association between TP53 Arg72Pro polymorphism and luncer susceptibility: evidence from 30,038 subjects. Lung. 2013;191(4):369–77.

    Article  CAS  PubMed  Google Scholar 

  43. Kiyohara C, Horiuchi T, Miyake Y, et al. Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. Oncol Rep. 2010;23(5):1361–8.

    Article  CAS  PubMed  Google Scholar 

  44. Wang S, Lan X, Tan S, et al. P53 codon 72 Arg/Pro polymorphism and lung cancer risk in asians: an updated meta analysis. Tumor Biol. 2013;34(5):2511–20.

    Article  CAS  Google Scholar 

  45. Liu D, Wang F, Guo X, et al. Association between P53 codon 72 genetic polymorphisms and tobacco use and lung cancer risk in Chinese population. Mol Biol Rep. 2013;40(1):645–9.

    Article  CAS  PubMed  Google Scholar 

  46. Caceres DD, Quinones LA, Schroeder JC, et al. Association between P53 codon72 genetic polymorphism and tobacco use and lung cancer risk. Lung. 2009;187(2):110–5.

    Article  CAS  PubMed  Google Scholar 

  47. Ye XH, Bu ZB, Feng J, et al. Association between the TP53 polymorphisms and lung cancer risk: a meta analysis. Mol Biol Rep. 2014;41(4):373–85.

    Article  CAS  PubMed  Google Scholar 

  48. Papadakis ED, Soulitzis L, Spandidos DA. Association of p53 codon 72 polytmorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer. 2002;87:1013–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kawajiri K, Nakachi K, Imai K, et al. Germline polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085–9.

    Article  CAS  PubMed  Google Scholar 

  50. Birgander R, Sjalander A, Rannug A, et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis. 1995;16:2233–6.

    Article  CAS  PubMed  Google Scholar 

  51. To-Figueras J, Gene M, Gomez-Catalan J, et al. Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1996;5:337–42.

    CAS  PubMed  Google Scholar 

  52. Pierce LM, Sivaraman L, Chang W, et al. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically divesre population. Cancer Epidemiol Biomarkers Prev. 2000;9:1199–204.

    CAS  PubMed  Google Scholar 

  53. Ignaszak-Szczepaniak M, Horst-Sikorska W, Sawicka J, Kaczmarek M, et al. The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients. Oncol Rep. 2006;16:65–71.

    CAS  PubMed  Google Scholar 

  54. Dumont P, Leu JI, Della Pietra AC, George DL, et al. The codon 72 polymorphic variants of p53have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.

    Article  CAS  PubMed  Google Scholar 

  55. Tagawa M, Murata M, Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Lett. 1998;128:93–9.

    Article  CAS  PubMed  Google Scholar 

  56. Li X, Dumont P, Della PA, Shelter C, et al. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem. 2005;280:24245–51.

    Article  CAS  PubMed  Google Scholar 

  57. Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Differ. 2006;13:916–20.

    Article  CAS  PubMed  Google Scholar 

  58. Sreeja L, Syamala V, Raveendran PB, et al. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest. 2008;26:41–6.

    Article  CAS  PubMed  Google Scholar 

  59. Jain N, Singh V, Hedau S, et al. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest. 2005;128:3999–4007.

    Article  CAS  PubMed  Google Scholar 

  60. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32(4):669–92.

    Article  PubMed  Google Scholar 

  61. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 59th WMA General Assembly Seoul, South Korea, October, 2008; 2008. http://www.wma.net/en/30publications/10policies/b3/index.html last accessed: Sept. 01, 2013.

  62. Daly AK, Monkman SC, Smart J, Steward A, Choletron S. Analysis of cytochrome P450 polymorphisms. Meth Mol Biol. 1998;107:405–22.

    CAS  Google Scholar 

  63. Chattopadhyay P, Pathore A, Mathur M, et al. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene. 1997;15:871–4.

    Article  CAS  PubMed  Google Scholar 

  64. Pinto GR, Yoshioka FK, Silva RL, et al. Prognostic value o TP53 Pro47Ser and Arg72Pro single nucleotide polymorphiosms nad the susceptibility to gliomas in individuals from southeast Brazil. Genet Mol Res. 2008;7:207–2016.

    Article  CAS  PubMed  Google Scholar 

  65. Vogelstein B, Kinzler K. Cancer genes and the pathways they control. Nature. 2004;10(8):789–99.

    CAS  Google Scholar 

  66. Lengaurer C, Kinzler K, Vogelstein B. Genetic instabilities in human cancer. Nature. 1998;396:643–9.

    Article  Google Scholar 

  67. Costa S, Pinto D, Pereira D, et al. Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction susceptibility on breast cancer. BMC Cancer. 2008;8:32.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Sjalander A, Birgander R, Hallmans G, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17:1313–6.

    Article  CAS  PubMed  Google Scholar 

  69. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild type p53 differ biochemically and bilogically. Mol Cell Biol. 1999;19:1092–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Lee JM, Lee YC, Yang SY, et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squmaous-cell carcinoma of the esophagus. Int J Cancer. 2000;89:458–64.

    Article  CAS  PubMed  Google Scholar 

  71. Hiyama T, Tanaka S, Kitadai Y, et al. p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter Pylori associated chronic gastritis. Int J Cancer. 2002;100:304–8.

    Article  CAS  PubMed  Google Scholar 

  72. Irarrazabal CE, Rojas C, Aracena C, et al. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett. 2003;144:69–76.

    Article  CAS  PubMed  Google Scholar 

  73. Zhu ZZ, Wang AZ, Jia HR, Jin XX. Association of the TP53 codon 72 polymorphism with colorectal cancer in Chinese population. Jpn J Clin Oncol. 2007;37:385–90.

    Article  PubMed  Google Scholar 

  74. Jin X, Wu X, Roth JA. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16:2205–8.

    Article  CAS  PubMed  Google Scholar 

  75. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers prev. 2000;9:1037–42.

    CAS  PubMed  Google Scholar 

  76. Miller DP, Liu G, Vivo ID. Combinations of the variants of GSTP1, GSTM1, and p53 are associated with an increased lung cancere risk. Cancer Res. 2002;62:2819–23.

    CAS  PubMed  Google Scholar 

  77. Yan L, Zhang D, Chen C, et al. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-alalysis. Int J Cancer. 2009;125:2903–11.

    Article  CAS  PubMed  Google Scholar 

  78. Piao JM, Kim HN, Song HR, et al. p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer. 2011;73:264–7.

    Article  PubMed  Google Scholar 

  79. Bergamaschi G, Merante S, Orlandi E, et al. TP53 codon 72 polymorphism in patients with chronic myleoid leukemia. Haematologica. 2004;89:868–9.

    CAS  PubMed  Google Scholar 

  80. Sakiyama T, Kohno T, Mimaki S, et al. Association of amino acid substitution polymorphism in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer. 2005;114:730–7.

    Article  CAS  PubMed  Google Scholar 

  81. Fernandez-Rubio A, Lopez-Cima MF, Gonzalez-Arriaga P, et al. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer. 2008;61:309–16.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors specially acknowledge the role of different personnel from Ahsania Mission Cancer and General Hospital, Dhaka Medical College Hospital, and Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, during this period of study. The authors are also thankful to the Department of Clinical Pharmacy and Pharmacology to give the opportunity to carry out the whole research work.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh

    Md. Shaki Mostaid, Maizbha Uddin Ahmed, Muhammad Shahdaat Bin Sayeed & Abul Hasnat

  2. Department of Pharmacy, Noakhali Science and Technology University, Sonapur, Noakhali, 3802, Bangladesh

    Mohammad Safiqul Islam

Authors
  1. Md. Shaki Mostaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maizbha Uddin Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohammad Safiqul Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muhammad Shahdaat Bin Sayeed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abul Hasnat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abul Hasnat.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mostaid, M.S., Ahmed, M.U., Islam, M.S. et al. Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population. Tumor Biol. 35, 10309–10317 (2014). https://doi.org/10.1007/s13277-014-2285-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2285-2

Keywords

Search

Navigation